Dongxu Shu

Title: Innovations of Dongxu Shu in RNAi Technology

Introduction

Dongxu Shu is a prominent inventor based in Madison, WI (US), known for his contributions to the field of RNA interference (RNAi) technology. He holds 4 patents that focus on innovative methods for inhibiting gene expression, particularly in the context of cancer treatment.

Latest Patents

One of his latest patents involves RNAi agents designed to inhibit the expression of HIF-2 alpha (EPAS1) gene. This patent details the use of double-stranded RNAi agents that can effectively target and inhibit HIF-2 alpha gene expression. The disclosure also includes pharmaceutical compositions that incorporate these RNAi agents, which may be linked to targeting ligands that have an affinity for integrins, such as alpha-v-beta-3 and alpha-v-beta-5 integrins. This innovative approach facilitates the delivery of these agents to cells and tissues, including clear cell renal cell carcinoma (ccRCC) cells and tumors. The application of these HIF-2 alpha RNAi agents in vivo has shown promise in inhibiting gene expression, offering potential treatment methods for various diseases, including ccRCC.

Another significant patent by Dongxu Shu describes synthetic αvβ6 integrin ligands that possess serum stability and affinity for the integrin αvβ6 receptor. These ligands are instrumental in delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells expressing integrin αvβ6. The described compositions and methods of use highlight the potential for enhanced cellular uptake of therapeutic agents.

Career Highlights

Dongxu Shu is currently associated with Arrowhead Pharmaceuticals, Inc., where he continues to advance his research in RNAi technology. His work is pivotal in developing innovative treatments that leverage the power of RNA interference to combat various diseases.

Collaborations

He collaborates with notable colleagues, including Zhen Li and Rui Zhu, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Dongxu Shu's contributions to RNAi technology exemplify the potential of innovative approaches in medical treatment. His patents reflect a commitment to advancing therapeutic strategies that can significantly impact patient care.